
ACTH fragment developed in Russia — nootropic and neuroprotector with effects on BDNF, NGF, and attention. Registered in Russian pharmacopoeia.
Ranges cited in research literature. Not a usage recommendation. For research use only.
Semax is a synthetic heptapeptide — Met-Glu-His-Phe-Pro-Gly-Pro — made of fragment 4-7 of adrenocorticotropic hormone (ACTH) plus the stabilizing Pro-Gly-Pro tail. It was developed in the 1980s at the Institute of Molecular Genetics in Moscow, under Igor Ashmarin and Nikolai Myasoedov, with the aim of keeping the ACTH fragment's effects on learning and memory without its hormonal activity: Semax does not stimulate the adrenal glands and does not meaningfully bind melanocortin receptors.
The best-documented mechanism is a rapid increase in BDNF and NGF expression and of their receptors (TrkB, TrkA) in hippocampus and cortex, with effects on synaptic plasticity, attention and working memory in animal models. Modulation of dopaminergic and serotonergic transmission has also been described, along with a reduced inflammatory response after cerebral ischemia in rodents, which gene-expression studies reflect in immune- and vascular-response genes.
In Russia it is registered as a nasal solution (0.1% and 1%) and has been used clinically in ischemic stroke, optic neuropathy and cognitive disorders, with trials published in Russian journals and no independent Western replication. It holds no FDA or EMA approval. The methionine at its N-terminus makes it oxidation-sensitive, a practical point for laboratory handling. Renova distributes it for research only.
| Class | Synthetic heptapeptide, ACTH(4-7) analog with a PGP tail |
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro (7 aa) |
| CAS | 80714-61-0 |
| Origin | Institute of Molecular Genetics, Moscow (Ashmarin, Myasoedov), 1980s |
| Described mechanisms | ↑ BDNF, NGF and Trk receptors; dopamine/serotonin modulation; immune- and vascular-response genes |
| Hormonal activity | No corticotropic effect; does not meaningfully activate melanocortin receptors |
| Clinical route | Intranasal (Russian registration); the SC route is a research convention |
| Stability | N-terminal methionine is oxidation-sensitive: protect from air and light once reconstituted |
No. ACTH fragment 4-7 keeps the nervous-system effects described for the hormone but loses the ability to stimulate the adrenals; Semax does not raise cortisol and does not act meaningfully on melanocortin receptors. It was designed precisely to separate the two functions.
In animal models it increases within hours the expression of BDNF and NGF, two neurotrophic factors, and of their TrkB and TrkA receptors in hippocampus and cortex. It is the mechanism most cited to explain its effects on memory and attention, and it distinguishes it from Selank, whose profile is more GABAergic.
It is registered as nasal drops and has been employed in ischemic stroke, optic neuropathy, encephalopathies and for cognitive support under high demand. The trials backing those uses are Russian and have not been replicated in the West. Outside Russia it is a research compound.
Because its first amino acid is a methionine, whose sulfur oxidizes to sulfoxide on contact with air and light, altering the molecule. In the laboratory it should be reconstituted shortly before the assay and the solution kept cold and shielded from light; our reconstitution guide details the handling.
Related reading: Semax and Selank: The Russian Peptide Nootropics · HHS and peptide compounding in the U.S.: the October 2026 policy and its 10 conditions
Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.
Your cart is empty